Invests in publicly traded life sciences companies globally. Focuses on biotechnology, pharmaceutical, and healthcare sectors. Now — the numbers.
This is an established company with proven profits.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
The market pays 7× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Against companies in its own sector, it looks cheaper than 87% of them.
No analyst target is on record for this company.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
For a bank, strength is measured by capital buffers and reserves — not cash minus debt.
The price looks reasonable next to what the company earns.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
Financial Strength: The capital buffer looks thin next to its class; less room to absorb a rough stretch.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
The net profit margin is 99% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 18% a year on average.
It pays out $2.24 per share each year — regular cash for whoever holds the stock.
Over the last 12 months, executives reported 25 sells against just 1 buy. Not an alarm bell by itself, but a number worth watching.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 17/100.
We grade companies — revenue, margins, balance sheets. This is a fund, so there is no report card to give. That is not a low grade; it is a different kind of thing.
One-line summary: a basket, not a business. Judge it by what it holds.